AN2 Therapeutics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period
AN2 Therapeutics, Inc. (ANTX) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period of 22.76 thousand shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod · last filed 2026-08-11
- AN2 Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for the quarter ending 2026-06-30 was 0.00 shares, a 100.00% decline year-over-year.
- AN2 Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for the quarter ending 2026-03-31 was 22.76K shares, a 80.47% decline year-over-year.
- AN2 Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for the quarter ending 2025-12-31 was 183.66K shares.
- AN2 Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for the quarter ending 2025-09-30 was 241.04K shares.
- AN2 Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for fiscal 2025 was 577.81K shares, a 18.78% decline from fiscal 2024.
- AN2 Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for fiscal 2024 was 711.43K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period 12 month |
|---|---|---|---|---|
| 2026-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | 22.76K shares 10-Q · filed 2026-08-11 | 206.42K shares derived: sum of 3 quarters · filed 2026-08-11 | 447.46K shares derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | 22.76K shares 10-Q · filed 2026-05-11 | 206.42K shares derived: sum of 2 quarters · filed 2026-05-11 | 447.46K shares derived: sum of 3 quarters · filed 2026-05-11 | 484.05K shares derived: sum of 4 quarters · filed 2026-05-11 |
| 2025-12-31 | 183.66K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | 424.70K shares derived: sum of 2 quarters · filed 2026-03-17 | 461.29K shares derived: sum of 3 quarters · filed 2026-03-17 | 577.81K shares 10-K · filed 2026-03-17 |
| 2025-09-30 | 241.04K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | 277.63K shares derived: sum of 2 quarters · filed 2025-11-12 | 394.15K shares 10-Q · filed 2025-11-12 | |
| 2025-06-30 | 36.59K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | 153.11K shares 10-Q · filed 2025-08-12 | ||
| 2025-03-31 | 116.52K shares 10-Q · filed 2025-05-13 | |||
| 2024-12-31 | 711.43K shares 10-K · filed 2025-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 |